Zacks Investment Research
30 Sept 2026, 19:35 UTC · 1h ago
Verdict
Headline takes no side. We score NVO +0.60 across two claims — strongly bullish.
+0.60strongly bullish
More positive than 78% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
The COMPETE SWITCH CV study found that patients increasing their Ozempic dose to 2 mg had a 6% lower risk of major adverse cardiovascular events (MACE) than those who switched to Mounjaro.
Newannounced September 30, 2026
So whatCompetitive clinical superiority in MACE risk could drive a shift in prescribing preferences, potentially reversing NVO's 22.2% YTD decline.
More positive than 94% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
In the real-world study, 36.9% of patients escalated to Ozempic 2 mg compared to only 5.7% who switched to Mounjaro by 720 days of follow-up.
Newannounced September 30, 2026
So whatThe low switch rate (5.7%) suggests high patient/physician inertia for Ozempic, supporting stable near-term market share for NVO.
More positive than 67% of claims this week
Which stocks this story touches
More positive than 78% of ticker scores this week
New real-world data shows Ozempic patients had a lower risk of major adverse cardiovascular events compared to those switching to Mounjaro.
More negative than 68% of ticker scores this week
Competing therapy Mounjaro showed a higher observed risk of major adverse cardiovascular events in a comparative study against Ozempic.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
1h ago
−1.0%
Price is moving against the score
$37.91 vs $38.31 close before publication (Sep 29) · not market-adjusted
NVO chart →
